SNPX vs. KTRA, CING, KZIA, CPHI, PTIX, SONN, GNPX, NEXI, YMTX, and DRUG
Should you be buying Synaptogenix stock or one of its competitors? The main competitors of Synaptogenix include Kintara Therapeutics (KTRA), Cingulate (CING), Kazia Therapeutics (KZIA), China Pharma (CPHI), Protagenic Therapeutics (PTIX), Sonnet BioTherapeutics (SONN), Genprex (GNPX), NexImmune (NEXI), Yumanity Therapeutics (YMTX), and Bright Minds Biosciences (DRUG). These companies are all part of the "pharmaceutical preparations" industry.
Kintara Therapeutics (NASDAQ:KTRA) and Synaptogenix (NASDAQ:SNPX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, community ranking, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.
Synaptogenix's return on equity of 0.00% beat Kintara Therapeutics' return on equity.
Kintara Therapeutics received 15 more outperform votes than Synaptogenix when rated by MarketBeat users. Likewise, 88.89% of users gave Kintara Therapeutics an outperform vote while only 50.00% of users gave Synaptogenix an outperform vote.
0.6% of Kintara Therapeutics shares are held by institutional investors. Comparatively, 10.3% of Synaptogenix shares are held by institutional investors. 4.8% of Kintara Therapeutics shares are held by insiders. Comparatively, 4.3% of Synaptogenix shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, Synaptogenix had 1 more articles in the media than Kintara Therapeutics. MarketBeat recorded 3 mentions for Synaptogenix and 2 mentions for Kintara Therapeutics. Synaptogenix's average media sentiment score of 0.46 beat Kintara Therapeutics' score of 0.36 indicating that Kintara Therapeutics is being referred to more favorably in the media.
Kintara Therapeutics has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500. Comparatively, Synaptogenix has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500.
Summary
Kintara Therapeutics beats Synaptogenix on 6 of the 11 factors compared between the two stocks.
Get Synaptogenix News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNPX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Synaptogenix Competitors List
Related Companies and Tools
